← Leaderboards
Milan Radovich
Indiana University Indianapolis
$370,652
Attributed
$370,652
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $199.4K · FY2018–19$200K$150K$100K$50K$0
'18
'19
Funding mix
By agency
NIH$370,652 · 1
By mechanism
R21$370,652 · 1
Top collaborators
No co-investigators on record.
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Xiongbin Lu$8,023,409
- Paul Richard Territo$22,416,914
- Xinna Zhang$3,467,211
- Bryan Paul Schneider$1,500,312
- Heather M O'Hagan$2,422,572
Others in their field
Other Emerging Leaders on “Aftercare”
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,888,963
- Bronwen Shaw · Medical College Of Wisconsin$19,182,557
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$13,559,983
- Ki Young Chung · Prisma Health - Upstate$8,495,983
- Deanna A Kulpa · Emory University$8,444,989
Research focus
AftercareAndrogen AntagonistsAntibody-Drug ConjugatesBaseBiological MarkersBiopsyBloodBreast Cancer ModelBreast Cancer PatientBurden Of IllnessCell SurfaceClinical TrialsCombined Modality TherapyDoseDrug CombinationsFinancial CompensationFrap1 GeneFutureGenomic AberrationsGenomicsImmunotherapyImproved OutcomeInhibitor/AntagonistAdvanced Breast Cancer
Grant awards (2)
Understanding the one-two punch: biomarkers of clinical response to a novel compensatory drug combination for metastatic TNBC$199,371
R21 · FY2019 · CA · contact PI
Understanding the one-two punch: biomarkers of clinical response to a novel compensatory drug combination for metastatic TNBC$171,281
R21 · FY2018 · CA · contact PI